select a format

Single User License
USD 2000 INR 129380
Site License
USD 4000 INR 258760
Corporate User License
USD 6000 INR 388140

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Optic Neuropathy-Pipeline Review, H2 2015

Optic Neuropathy-Pipeline Review, H2 2015


  • Products Id :- GMDHC7019IDB
  • |
  • Pages: 50
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Optic Neuropathy-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Optic Neuropathy-Pipeline Review, H2 2015', provides an overview of the Optic Neuropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Optic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Optic Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Optic Neuropathy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Optic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Optic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Optic Neuropathy Overview 6

Therapeutics Development 7

Pipeline Products for Optic Neuropathy-Overview 7

Pipeline Products for Optic Neuropathy-Comparative Analysis 8

Optic Neuropathy-Therapeutics under Development by Companies 9

Optic Neuropathy-Therapeutics under Investigation by Universities/Institutes 10

Optic Neuropathy-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Optic Neuropathy-Products under Development by Companies 13

Optic Neuropathy-Products under Investigation by Universities/Institutes 14

Optic Neuropathy-Companies Involved in Therapeutics Development 15

Inotek Pharmaceuticals Corporation 15

Neurotech Pharmaceuticals, Inc. 16

PharmatrophiX, Inc. 17

Quark Pharmaceuticals, Inc. 18

Regenera Pharma Ltd. 19

Optic Neuropathy-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

BA-240-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

NT-501-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

QPI-1007-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

RPh-201-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules for CNS Disorders and Ophthalmology-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Synthetic Peptide to Inhibit Connexin for Optic Neuropathy-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

trabodenoson-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Optic Neuropathy-Recent Pipeline Updates 44

Optic Neuropathy-Dormant Projects 47

Optic Neuropathy-Product Development Milestones 48

Featured News & Press Releases 48

Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy 48

Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

Number of Products under Development for Optic Neuropathy, H2 2015 7

Number of Products under Development for Optic Neuropathy-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Number of Products under Investigation by Universities/Institutes, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 11

Comparative Analysis by Early Stage Development, H2 2015 12

Products under Development by Companies, H2 2015 13

Products under Investigation by Universities/Institutes, H2 2015 14

Optic Neuropathy-Pipeline by Inotek Pharmaceuticals Corporation, H2 2015 15

Optic Neuropathy-Pipeline by Neurotech Pharmaceuticals, Inc., H2 2015 16

Optic Neuropathy-Pipeline by PharmatrophiX, Inc., H2 2015 17

Optic Neuropathy-Pipeline by Quark Pharmaceuticals, Inc., H2 2015 18

Optic Neuropathy-Pipeline by Regenera Pharma Ltd., H2 2015 19

Assessment by Monotherapy Products, H2 2015 20

Number of Products by Stage and Target, H2 2015 22

Number of Products by Stage and Mechanism of Action, H2 2015 24

Number of Products by Stage and Route of Administration, H2 2015 26

Number of Products by Stage and Molecule Type, H2 2015 28

Optic Neuropathy Therapeutics-Recent Pipeline Updates, H2 2015 44

Optic Neuropathy-Dormant Projects, H2 2015 47

List of Figures

Number of Products under Development for Optic Neuropathy, H2 2015 7

Number of Products under Development for Optic Neuropathy-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Number of Products under Investigation by Universities/Institutes, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 11

Comparative Analysis by Early Stage Products, H2 2015 12

Assessment by Monotherapy Products, H2 2015 20

Number of Products by Top 10 Targets, H2 2015 21

Number of Products by Stage and Top 10 Targets, H2 2015 21

Number of Products by Top 10 Mechanism of Actions, H2 2015 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 23

Number of Products by Top 10 Routes of Administration, H2 2015 25

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 25

Number of Products by Top 10 Molecule Types, H2 2015 27

Number of Products by Stage and Top 10 Molecule Types, H2 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Inotek Pharmaceuticals Corporation

Neurotech Pharmaceuticals, Inc.

PharmatrophiX, Inc.

Quark Pharmaceuticals, Inc.

Regenera Pharma Ltd.

Optic Neuropathy Therapeutic Products under Development, Key Players in Optic Neuropathy Therapeutics, Optic Neuropathy Pipeline Overview, Optic Neuropathy Pipeline, Optic Neuropathy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com